Navidea Biopharmaceuticals, Inc.
NAVBDelisted Jan 16, 2024- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000810509
Navidea Biopharmaceuticals, Inc. was delisted on Jan 16, 2024; its insiders filed their last Form 4 on Dec 5, 2023; 24 institutions reported holding it in 13F filings for Q3 2023, worth $225.8K in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 24
- Q3 2023, +1 vs. previous quarter
- 13F value
- $225.8K
- Reported value at the end of Q3 2023
- Superinvestors holding
- 0
- At the end of Q3 2023
Superinvestors holding NAVB, Q3 2023
No superinvestor reported holding NAVB at the end of Q3 2023.
Latest insider trades
Open-market purchases and sales by Navidea Biopharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2023 (view filing) | Jun 1 | 14 daysLate | Scott John K Jr.Director, 10% Owner | PPurchase | +11.5M | $0.104 | +$1.20M | –12.0K after | Derivative |
| Sep 1, 2022 (view filing) | Aug 30 | 2 days | Witter Malcolm GDirector | PPurchase | +511.1K | – | – | –115 after | Derivative2 lots |
| Sep 1, 2022 (view filing) | Aug 30 | 2 days | Scott John K Jr.Director, 10% Owner | SSale | −2.17M | $1.10 | −$2.40M | –0 after | Derivative |
| Sep 1, 2022 (view filing) | Aug 30 | 2 days | Scott John K Jr.Director, 10% Owner | PPurchase | +10.7M | – | – | –2.40K after | Derivative2 lots |
| May 3, 2022 (view filing) | Apr 10 | 23 daysLate | Scott John K Jr.Director, 10% Owner | PPurchaseSeries G Redeemable Preferred Stock | +3.26K | – | – | New position3.26K after | |
| May 3, 2022 (view filing) | Apr 10 | 23 daysLate | Scott John K Jr.Director, 10% Owner | SSale | −2.17M | $0.0529 | −$115.0K | –0 after | Derivative |
| May 3, 2022 (view filing) | Apr 10 | 23 daysLate | Scott John K Jr.Director, 10% Owner | PPurchase | +2.17M | $0.0006 | +$1.39K | –1.74K after | Derivative |
| Sep 17, 2021 (view filing) | Sep 17 | Same day | Witter Malcolm GDirector | PPurchase | +20.0K | $1.60 | +$32.0K | +25.6%98.3K after | |
| Jul 26, 2021 (view filing) | Jul 26 | Same day | Witter Malcolm GDirector | PPurchase | +15.0K | $1.70 | +$25.5K | +23.7%78.3K after |
Top 10 13F holders, Q3 2023
The largest institutional positions in Navidea Biopharmaceuticals, Inc. at the end of Q3 2023; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Allred Capital Management, LLC | 466,688 | $41.9K | 0.02% | +172,850+58.8% | Added |
| State Street Corp | 412,743 | $37.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 368,830 | $33.1K | 0.00% | +267,832+265.2% | Added |
| Virtu Financial LLC | 333,069 | $30.0K | 0.00% | +333,069 | New |
| Vanguard Group Inc | 276,491 | $24.8K | 0.00% | 00.0% | Unchanged |
| Warberg Asset Management LLC | 194,997 | $17.5K | 0.01% | +194,997 | New |
| UBS Group AG | 149,612 | $13.5K | 0.00% | +149,362+59,744.8% | Added |
| BlackRock Inc. | 113,030 | $10.1K | 0.00% | +102+0.1% | Added |
| Level Four Advisory Services, LLC | 55,555 | $4.98K | 0.00% | +55,555 | New |
| Boothbay Fund Management, LLC | 40,000 | $3.59K | 0.00% | 00.0% | Unchanged |